Table 4 Clinical outcomes and antibiotic use before and after the intervention in the matched cohorts
Before | After | |||
|---|---|---|---|---|
n = 97 | n = 97 | |||
Outcome = effective, n (%) | 77 | (79.4) | 84 | (86.6) |
Excellent | 12 | (12.4) | 13 | (13.4) |
Effective | 65 | (67.0) | 71 | (73.2) |
Treatment duration(days), mean (SD) | 11.07 | (7.43) | 10.51 | (4.88) |
Switching Antibiotics = TRUE, n (%) | 31 | (32.0) | 14 | (14.4) |
Adverse effect = TRUE, n (%) | 5 | (5.2) | 3 | (3.1) |
Antibiotics, n (%) | ||||
Anti-MRSA | 6 | (6.2) | 3 | (3.1) |
Cephalosporine (2nd) | 8 | (8.2) | 8 | (8.2) |
Cephalosporine (3rd /4th) | 3 | (3.1) | 1 | (1.0) |
Carbapenem | 32 | (33.0) | 11 | (12.4) |
MEPM | 24 | (24.7) | 9 | (9.3) |
DRPM | 7 | (7.2) | 1 | (1.0) |
IPM/CS | 1 | (1.0) | 1 | (1.0) |
βl-Penicillin | 77 | (79.4) | 47 | (48.5) |
SBT/ABPC | 29 | (29.9) | 10 | (10.3) |
TAZ/PIPC | 48 | (49.5) | 37 | (38.1) |
βl-Cephalosporine | 11 | (11.3) | 46 | (47.4) |
SBT/CPZ | 11 | (11.3) | 46 | (47.4) |
Others | 4 | (4.1) | 1 | (1.0) |